SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3559 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1807As George as mentioned in the past, don't see the purpose of a bispecific wiFelix B-10/22/2015
1806Lucentis 3Q US sales decline further, Roche moved VEGF/Ang2 biMab into P2.Miljenko Zuanic-10/22/2015
1805I responded, and have no idea what happen to my reply. They are not yet at 30%! Miljenko Zuanic-10/12/2015
1804Is this a true-up that’s contractually allowed under a standstill agreement (as DewDiligence_on_SI-10/9/2015
1803Is something wrong with sanofi? Didn't they hear about our (US) brave presiMiljenko Zuanic-10/9/2015
1802ESRX: siliconinvestor.comDewDiligence_on_SI-10/6/2015
1801For them REGN is doing safety P1 trial (https://clinicaltrials.gov/ct2/show/NCT0Miljenko Zuanic-10/3/2015
1800Why did Regeneron license P3 NGF-program to Japanese comps. so cheap? Are they Miljenko Zuanic-10/3/2015
1799Does SNY have permission to true-up its REGN equity stake whenever it falls beloDewDiligence_on_SI-9/28/2015
1798<<Sanofi sees value in REGN stock.>> Looks like street does not! :-Miljenko Zuanic-9/28/2015
1797Sanofi sees value in REGN stock. investor.regeneron.comBiotech Jim-9/26/2015
1796Indeed! (eom)Miljenko Zuanic-8/30/2015
1795Praluent versus Repatha! Who care? Nobody? RIGHT? NO! Scream Mr. Market! NMiljenko Zuanic-8/27/2015
1794Yes, they usual sell near-before option expiration. Except LS (big cheater) who Miljenko Zuanic-8/20/2015
1793Like I have been saying for the past 5 or even more years, watch to see if and hBiotech Jim-8/20/2015
1792Praluent: WHO CARE! AMGN' PDUFA: WHO CARE! Did you, me, or anyone else pMiljenko Zuanic-8/20/2015
1791I don't think it means much since anyone at the C level has plenty of optionFelix B-8/20/2015
1790That current REGN MC is by every and any means stretched is no secret to anyoneMiljenko Zuanic18/19/2015
1789I wonder why? REGN to go solo or find a partner?Felix B-8/5/2015
1788REGN2222 is for "niche" market, so does not fit Sanofi boutique. WelMiljenko Zuanic-8/4/2015
1787Footnotes #3 and #5 to this quarter's earnings report: (3) The Company'Biotech Jim-8/4/2015
1786Regeneron Reports Second Quarter 2015 Financial and Operating Results (August 4,Biotech Jim18/4/2015
1785I am sure costs will be much lower if this sign exclusivity deals with the payerFelix B-7/29/2015
1784Pts population is wide open (statin intolerant included), but how will payers reMiljenko Zuanic-7/27/2015
1783From the FDA July 24, 2015 PR on Praluent approval, but we still await the labelBiotech Jim-7/27/2015
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News